Morgis Rebecca, Wong Ashley, Witmer Lisa M, Kantner Anne, Mendez-Miller Megan, Ramirez Sarah I, Ruffin Mack T, Moss Jennifer L
Penn State College of Medicine, Hershey, Pennsylvania, USA.
Womens Health Rep (New Rochelle). 2025 Mar 28;6(1):377-383. doi: 10.1089/whr.2024.0180. eCollection 2025.
Cervical cancer screening rates fall below national goals. At-home self-sampled tests for human papillomavirus (HPV) may improve screening rates. This study assesses the acceptability of self-sampled HPV testing with respect to motivating factors and preference among average-risk patients (undergoing routine screening) and high-risk patients (receiving follow-up care after abnormal screening results).
This cross-sectional study sample consisted of 46 participants (female, ages 30-65), including average-risk (n = 35) and high-risk (n = 11) patients, who had already received clinician-collected cervical cancer screening. Participants completed a self-sampled HPV test and a survey. Motivators included cervical cancer screening facilitators, sexual history, health care factors, and feelings during self-sampled test. We analyzed the relationships between these constructs and test modality preference for their next cervical cancer screening (i.e., self-sampled HPV testing at home vs. other preference).
Few participants experienced negative feelings during self-sampled HPV testing (uncomfortable: 20%; anxious: 22%; and unpleasant: 15%). Overall, 57% of participants would prefer to complete a self-sampled HPV test at home for their next cervical cancer screening compared with other test options. Test modality preference for their next cervical cancer screening did not differ for average- versus high-risk patients, and it did not vary by any of the motivating factors we assessed (all > 0.05).
Acceptability of self-sampled HPV testing at home is high, with little difference in attitudes observed across patient characteristics. These findings demonstrate that self-sampled HPV testing may be an effective tool for increasing cervical cancer screening, even among high-risk patients who have previously had abnormal screening results.
宫颈癌筛查率低于国家目标。人乳头瘤病毒(HPV)家庭自采样检测可能提高筛查率。本研究评估了自采样HPV检测在平均风险患者(接受常规筛查)和高风险患者(筛查结果异常后接受后续护理)中的动机因素和偏好方面的可接受性。
本横断面研究样本包括46名参与者(女性,年龄30 - 65岁),包括平均风险患者(n = 35)和高风险患者(n = 11),她们已经接受了临床医生采集的宫颈癌筛查。参与者完成了一次自采样HPV检测和一项调查。动机因素包括宫颈癌筛查促进因素、性病史、医疗保健因素以及自采样检测期间的感受。我们分析了这些因素与她们下次宫颈癌筛查的检测方式偏好(即在家进行自采样HPV检测与其他偏好)之间的关系。
很少有参与者在自采样HPV检测过程中体验到负面情绪(不舒服:20%;焦虑:22%;不愉快:15%)。总体而言,57%的参与者更愿意在家中完成自采样HPV检测用于下次宫颈癌筛查,与其他检测选项相比。平均风险与高风险患者在下次宫颈癌筛查的检测方式偏好上没有差异,并且在我们评估的任何动机因素方面也没有变化(所有P>0.05)。
在家进行自采样HPV检测的可接受性很高,不同患者特征的态度差异不大。这些发现表明,自采样HPV检测可能是提高宫颈癌筛查率的有效工具,即使在先前筛查结果异常的高风险患者中也是如此。